Nikolay Savchuk - Dec 29, 2024 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)

Role
Chief Operating Officer, Director, 10%+ Owner
Signature
/s/ Nikolay Savchuk
Stock symbol
TRAW
Transactions as of
Dec 29, 2024
Transactions value $
$0
Form type
4
Date filed
1/27/2025, 07:00 PM
Previous filing
Nov 5, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRAW Pre-Funded Warrant (right to buy) Purchase +96.3K 96.3K Dec 29, 2024 Common Stock 96.3K $0.01 By TPAV, LLC F1, F2, F3, F4
transaction TRAW Series A Warrant (right to buy) Purchase +96.3K 96.3K Dec 29, 2024 Common Stock 96.3K $13.42 By TPAV, LLC F3, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules.
F2 The Pre-Funded Warrants do not expire.
F3 The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.
F4 The Pre-Funded Warrants and Series A Warrants are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F5 The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules.
F6 The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data.